Using biomarkers to improve treatment for high-risk bladder cancer
Biomarker guided combinations for treating high-risk bladder cancer
This study is looking at new ways to help people with high-risk bladder cancer feel better by testing different combinations of chemotherapy drugs, including Gemcitabine, and finding out which treatments work best for them based on their unique needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-10883703 on NIH RePORTER |
What this research studies
This research focuses on improving treatment outcomes for patients with high-risk bladder cancer, particularly those with muscle-invasive bladder cancer (MIBC). The study evaluates two specific combinations of chemotherapy drugs, particularly Gemcitabine, to enhance effectiveness and reduce the risk of metastasis. It aims to identify biomarkers that can guide treatment decisions, potentially leading to more personalized and effective therapies. By understanding the mechanisms of drug resistance, the research seeks to optimize treatment protocols for better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade muscle-invasive bladder cancer who are at risk for metastasis.
Not a fit: Patients with low-grade bladder cancer or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for high-risk bladder cancer, potentially reducing recurrence and improving survival rates.
How similar studies have performed: Previous research has shown promise in using biomarker-guided therapies for other cancers, suggesting potential success for this novel approach in bladder cancer.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Lokeshwar, Vinata B — Augusta University
- Study coordinator: Lokeshwar, Vinata B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.